Abstract: A third generation of CAR-CD30 T cells is for treatment of CD30+ Tumors such as lymphoid malignancies, leukemia, and solid tumors. A CD30 chimeric antigen receptor includes, from the N-terminus to the C? terminus, a signal peptide, which is linked by a first linker to an anti CD30 single chain antibody domain from AC10 hybridoma including the AC10 VL sequence and the AC10 VH sequence. The AC10 VL and VH sequences are linked by a second linker.

Abstract: The present invention relates to a chimeric antigen receptor (CAR) molecule containing, from the N-terminus to the C-terminus: a) an extracellular domain and transmembrane domain of human CD19, b) an antigen binding domain, c) a spacer domain, d) a transmembrane domain, and e) a cytoplasmatic domain, preferably wherein the CAR is a CD123 specific CAR (CD123 CAR) and the antigen binding domain includes a VL and/or VH from a monoclonal anti-CD123 antibody, more preferably the antigen binding domain includes a single chain variable fragment (scFv) that specifically binds to CD123.

Abstract: Provided are methods of making innate immune cell compositions containing gamma.delta (??) T cells and/or Natural Killer (NK) cells, and the resulting compositions and related products of manufacture and kits for use in cancer and infectious disease therapy. The methods provided herein permit tailoring of the relative amounts of gamma.delta (??) T cells and Natural Killer (NK) cells in the compositions. for cellular therapies against a wide variety of cancers and infectious diseases. The resulting compositions can further be used to generate compositions containing either NK cells alone or gamma.delta T cells alone, for immune cellular therapies. The compositions provided herein also can be genetically altered: the gamma delta T cells and Natural Killer cells are modified to express chimeric antigen receptors (CARs) or exogenous T cell receptors (TCRs), which can be used to target any cell surface molecule either directly or indirectly, e.g., a marker on a cancer cell or an infected cell.

Abstract: A third generation of CAR-CD30 T cells is for treatment of CD30+ Tumors such as lymphoid malignancies, leukemia, solid tumors. A CD30 chimeric antigen receptor includes, from the N-terminus to the C-terminus, a signal peptide, which is linked by a first linker to an anti CD30 single chain antibody domain from AC10 hybridoma including the AC10 VL sequence and the AC10 VH sequence. The AC10 VL and VH sequences are linked by a second linker.

Abstract: Provided are methods of making innate immune cell compositions containing gamma.delta (??) T cells and/or Natural Killer (NK) cells, and the resulting compositions and related products of manufacture and kits for use in cancer and infectious disease therapy. The methods provided herein permit tailoring of the relative amounts of gamma.delta (??) T cells and Natural Killer (NK) cells in the compositions, for cellular therapies against a wide variety of cancers and infectious diseases. The resulting compositions can further be used to generate compositions containing either NK cells alone or gamma.delta T cells alone, for immune cellular therapies. The compositions provided herein also can be genetically altered: the gamma delta T cells and Natural Killer cells are modified to express chimeric antigen receptors (CARS) or exogenous T cell receptors (TCRs), which can be used to target any cell surface molecule either directly or indirectly, e.g., a marker on a cancer cell or an infected cell.